Etidronate Disodium and Feiba

• Generic Name: etidronate
• Dosage Forms: n.a.
• Other Brand Names: Didronel, Didronel IV.

Used in the treatment of moderate to severe symptomatic Paget disease of bone (osteitis deformans).

Efficacy not established in asymptomatic patients. May consider prophylactic treatment in patients with extensive involvement of the skull or spinal column and the possibility of irreversible neurologic damage or in those with extensive involvement threatening major joints or weight-bearing bones.

Less effective than risedronate or alendronate in the treatment of moderate to severe Paget disease of bone.

Relapse generally tends to occur within about 3–24 months in patients most likely to relapse (e.g., higher pretreatment markers of bone turnover).

Resistance is most likely to develop in patients receiving >1 course of therapy per year or those with higher pretreatment indices of bone turnover.

Used in the prevention and treatment of heterotopic ossification (myositis ossificans, ectopic calcification, periarticular ossification, or paraosteoarthropathy) following total hip arthroplasty or resulting from spinal cord injury.

Efficacy not established for treatment of idiopathic heterotopic ossification or heterotopic ossification associated with conditions other than total hip arthroplasty or spinal cord injury.

Bisphosphonates, including etidronate, have been used effectively for the prevention and treatment of glucocorticoid-induced osteoporosis.

• Generic Name: anti-inhibitor coagulant complex
• Dosage Forms: n.a.
• Other Brand Names: Feiba, Feiba VH Immuno, Autoplex T, Feiba NF

Feiba is used in people who have hemophilia and have developed antibodies to clotting factor medications.

Hemophilia, an inherited blood-clotting disorder, is often treated with medicines containing clotting factors that help control bleeding. When the body develops antibodies or "inhibitors" to the clotting factor, this treatment becomes less effective in preventing bleeding episodes. Feiba works by bypassing the effects of these inhibitors to improve blood clotting and decrease the risk of bleeding.

Feiba is used to treat or prevent bleeding episodes in people with hemophilia A or B who have developed inhibitors. Feiba is also used to control bleeding related to surgery in people with hemophilia and inhibitors. This medicine is not for treating bleeding episodes in people who do not have inhibitors.

Feiba may also be used for purposes not listed in this medication guide.